SUBSCRIBE
SUBSCRIBE

Phase 1

Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
MD Anderson Cancer Center Postdoc Faked Results Of Novartis AG Brain Tumor Study
August 1, 2014
 · 
2 min read
Drug Development
Double Whammy Gene Therapy Clears HIV From Body, Sangamo BioSciences, Inc. Reveals
September 23, 2011
 · 
1 min read
Drug Development
Basilea Pharmaceutica’s Antibiotic BAL30072 Shows Activity against Superbugs Expressing the NDM-1 Resistance Factor
May 9, 2011
 · 
8 min read
Drug Development
Novel Drug Boosts EPO Release in Dialysis Patients, Friedrich Alexander University Study
December 1, 2010
 · 
1 min read
Drug Development
Conjugate Drug Shows Benefit in Lymphoma, University of Texas Study
November 4, 2010
 · 
1 min read
Drug Development
BRAF Kinase Inhibitor Shrinks Melanoma Brain Metastases, Institute Gustave Roussy Study
October 26, 2010
 · 
1 min read
Drug Development
New Melanoma Drug May Shrink Brain Tumors, Melanoma Institute Australia Study
October 11, 2010
 · 
1 min read
Drug Development
Bone Loss Seen Early in Inflammatory Disorders, VU University Medical Center Study
August 18, 2010
 · 
1 min read
Drug Development
Renovo Ltd.'s Medication May Improve Scar Healing, University of Manchester Studies
April 10, 2009
 · 
1 min read
Drug Development
Vaccine To Prevent Colon Cancer Being Tested In Patients, University of Pennsylvania School of Medicine Study
March 25, 2009
 · 
1 min read
Load More
PRESS RELEASES
Press Releases
Aramis Biotechnologies announces the achievement of an important milestone with the start of a Phase 1/2 clinical trial of its vaccine in development against seasonal influenza in 728 participants
February 26, 2026
 · 
2 min read
Press Releases
New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors
February 26, 2026
 · 
7 min read
Press Releases
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
February 26, 2026
 · 
3 min read
Press Releases
Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership
February 26, 2026
 · 
5 min read
Press Releases
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
February 26, 2026
 · 
7 min read
Press Releases
Asahi Kasei Pharma Strengthens Preclinical Pipeline Through Exclusive Global License Agreement with Alchemedicine for Novel Lead Compounds
February 26, 2026
 · 
2 min read
Press Releases
Kivu Bioscience Presents KIVU-305 Preclinical Data at World ADC London 2026 and Advances into Phase 1 Clinical Trial
February 26, 2026
 · 
3 min read
Press Releases
Mahzi Therapeutics Announces First Patient Dosed in Phase 1/2 UNITE Study of MZ-1866 for Pitt Hopkins Syndrome
February 26, 2026
 · 
4 min read
Press Releases
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
February 25, 2026
 · 
11 min read
Press Releases
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
February 25, 2026
 · 
5 min read
Press Releases
Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
February 25, 2026
 · 
8 min read
Press Releases
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
February 25, 2026
 · 
7 min read
Press Releases
Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
February 25, 2026
 · 
6 min read
Press Releases
Vico Therapeutics Announces Patient Dosing in Twice-Annual Regimen of VO659 in Phase 1/2 Trial in Huntington’s Disease, Spinocerebellar Ataxia Type 3 and Type 1
February 24, 2026
 · 
3 min read
Press Releases
Cartography Biosciences Doses First Patient in Phase 1 Trial of CBI-1214, a Highly Specific T-Cell Engager for the Treatment of Colorectal Cancer
February 24, 2026
 · 
4 min read
Press Releases
AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics’ Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)
February 24, 2026
 · 
4 min read
Press Releases
Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)
February 24, 2026
 · 
4 min read
Press Releases
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
February 24, 2026
 · 
10 min read
Press Releases
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
February 24, 2026
 · 
6 min read
Press Releases
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
February 24, 2026
 · 
11 min read
Load More